Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Oncology · Hereditary Breast and Ovarian Cancer Syndrome

Surveillance and Prevention Strategies

At a Glance

Individuals with BRCA mutations or HBOC syndrome require proactive cancer surveillance. Standard guidelines include annual breast MRIs starting at age 25, mammograms at age 30, and PSA testing for men at 40. Chemoprevention medications like tamoxifen can also help lower cancer risk.

Managing Hereditary Breast and Ovarian Cancer (HBOC) syndrome is about proactive partnership with your medical team. The National Comprehensive Cancer Network (NCCN) provides a “gold standard” roadmap for care, ensuring that carriers of BRCA1 or BRCA2 mutations receive the most effective screenings and prevention options available [1][2].

Breast Cancer Surveillance

Because carriers are at high risk for breast cancer, the goal of screening is to find any changes at the earliest, most treatable stage. The standard of care involves using two different imaging tools because they “see” things differently [3].

  • Breast MRI (Annual): Starting at age 25. MRI is highly sensitive and is the primary tool for younger women who often have denser breast tissue [1][3].
  • Mammography (Annual): Starting at age 30. This is typically added to the annual MRI schedule [1].

Often, doctors will “stagger” these tests—for example, having an MRI in January and a mammogram in July—so the breasts are being checked every six months [1].

Prostate Cancer Screening for Men

Men with BRCA mutations, particularly BRCA2, have a higher risk of developing aggressive prostate cancer [2][4].

  • PSA Screening: The NCCN recommends that men with BRCA1 or BRCA2 mutations begin annual Prostate-Specific Antigen (PSA) blood testing starting at age 40 [2].
  • Why it Matters: In BRCA carriers, prostate cancer can move more quickly, so early and regular monitoring is essential to catch it before it spreads [4][5].

Pancreatic Cancer Considerations

Pancreatic cancer screening is not universal for all BRCA carriers; it is generally reserved for those at the highest risk [6][7].

  • Criteria: You are typically eligible for screening if you have a BRCA1/2 mutation and at least one first-degree relative (parent, sibling, or child) who has had pancreatic cancer [8][9].
  • The Tests: Screening usually involves specialized imaging like Endoscopic Ultrasound (EUS) or an MRI/MRCP of the pancreas, typically starting around age 50 (or 10 years younger than the relative’s diagnosis) [10][2].

Chemoprevention: Using Medicine as a Shield

Chemoprevention refers to using specific medications to lower the risk of cancer developing or returning [11].

  • Primary Prevention: Medicines like Tamoxifen or Raloxifene have been shown to significantly reduce the risk of a first breast cancer diagnosis in both BRCA1 and BRCA2 carriers [11][12].
  • Contralateral Prevention: For those who have already had cancer in one breast, Tamoxifen can significantly lower the risk of a new cancer forming in the other breast [12].
  • Important Note: These medications can have side effects, such as a small increase in the risk of blood clots or, specifically with Tamoxifen in BRCA1 carriers, a risk of endometrial cancer that must be discussed with your doctor [13][14].

Standard of Care Checklist

Use this to ensure your care aligns with current guidelines:

  1. Age 25: Annual Breast MRI started?
  2. Age 30: Annual Mammogram added?
  3. Age 40 (Men): Annual PSA screening started?
  4. Any Age: Has the option of chemoprevention (like Tamoxifen) been discussed?
  5. Family History: If a relative had pancreatic cancer, has a screening plan been made? [1][2]

Common questions in this guide

What is the recommended breast cancer screening schedule for BRCA carriers?
The standard of care recommends an annual breast MRI starting at age 25, and an annual mammogram starting at age 30. Doctors often stagger these tests every six months for continuous monitoring.
Do men with BRCA mutations need specific cancer screenings?
Yes, men with BRCA mutations, especially BRCA2, have a higher risk of aggressive prostate cancer. They should begin annual Prostate-Specific Antigen (PSA) blood testing starting at age 40.
Should all BRCA carriers be screened for pancreatic cancer?
Pancreatic cancer screening is usually reserved for BRCA carriers who also have at least one first-degree relative who had the disease. Screening typically involves specialized imaging like an Endoscopic Ultrasound or MRI starting around age 50.
What is chemoprevention for hereditary breast cancer?
Chemoprevention involves using medications like tamoxifen or raloxifene to lower the risk of developing breast cancer. These medicines can significantly reduce the risk of a first diagnosis or prevent a new cancer from forming in the other breast.
What are the risks of taking tamoxifen for breast cancer prevention?
While tamoxifen lowers breast cancer risk, it can have side effects like a small increased risk of blood clots. In BRCA1 carriers, it may also slightly increase the risk of endometrial cancer, which you should discuss with your doctor.

Questions for Your Doctor

5 questions

  • •Am I currently receiving the full range of screenings (MRI and mammogram) recommended for my age and gene mutation?
  • •Based on my family history, do I qualify for pancreatic cancer screening, and at what age should that begin?
  • •What are the pros and cons of starting chemoprevention like tamoxifen versus choosing more intensive screening?
  • •For the men in my family with this mutation, when and how often should they have their PSA levels checked?
  • •If I have a BRCA1 mutation, how do we balance the benefits of tamoxifen with the potential risks for endometrial cancer?

Questions for You

3 questions

  • •How do I feel about the trade-off between the side effects of medications (like tamoxifen) and the benefit of reducing my cancer risk?
  • •Am I comfortable with a schedule that involves multiple imaging appointments (MRI and mammogram) throughout the year?
  • •Is there anyone in my immediate family (parent, sibling, child) who has had pancreatic cancer?

References

References (14)
  1. 1

    Beyond BRCA: Review of Hereditary Syndromes Predisposing to Breast Cancer.

    Nguyen JV, Thomas MH

    Journal of breast imaging 2019; (1(2)):84-91 doi:10.1093/jbi/wbz014.

    PMID: 38424924
  2. 2

    Clinical risk management of breast, ovarian, pancreatic, and prostatic cancers for BRCA1/2 variant carriers in Japan.

    Ueki A, Yoshida R, Kosaka T, Matsubayashi H

    Journal of human genetics 2023; (68(8)):517-526 doi:10.1038/s10038-023-01153-1.

    PMID: 37088789
  3. 3

    Contrast-enhanced MRI for breast cancer screening.

    Mann RM, Kuhl CK, Moy L

    Journal of magnetic resonance imaging : JMRI 2019; (50(2)):377-390 doi:10.1002/jmri.26654.

    PMID: 30659696
  4. 4

    Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.

    Nyberg T, Frost D, Barrowdale D, et al.

    European urology 2020; (77(1)):24-35 doi:10.1016/j.eururo.2019.08.025.

    PMID: 31495749
  5. 5

    The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.

    Oh M, Alkhushaym N, Fallatah S, et al.

    The Prostate 2019; (79(8)):880-895 doi:10.1002/pros.23795.

    PMID: 30900310
  6. 6

    Hereditary pancreatic cancer.

    Abe K, Kitago M, Kitagawa Y, Hirasawa A

    International journal of clinical oncology 2021; (26(10)):1784-1792 doi:10.1007/s10147-021-02015-6.

    PMID: 34476650
  7. 7

    Pancreatic Cancer in Hereditary Breast and Ovarian Cancer Syndrome: Is Early Detection Possible?

    Abe K, Kitago M, Kobayashi Y, et al.

    The Keio journal of medicine 2025; (74(3)):146-150 doi:10.2302/kjm.2024-0018-OA.

    PMID: 40254464
  8. 8

    Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer.

    Ohmoto A, Yachida S, Morizane C

    International journal of molecular sciences 2019; (20(3)) doi:10.3390/ijms20030561.

    PMID: 30699894
  9. 9

    Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance.

    Abe T, Blackford AL, Tamura K, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(13)):1070-1080 doi:10.1200/JCO.18.01512.

    PMID: 30883245
  10. 10

    Endoscopic innovations in diagnosis and management of pancreatic cancer: a narrative review and future directions.

    Harne PS, Harne V, Wray C, Thosani N

    Therapeutic advances in gastroenterology 2024; (17()):17562848241297434 doi:10.1177/17562848241297434.

    PMID: 39664230
  11. 11

    Risk-benefits assessment of tamoxifen or raloxifene as chemoprevention for risk reduction of breast cancer among BRCA1 and BRCA2 carriers: a meta-analysis.

    Alwashmi ASS, Khan NU, Chen T

    Scientific reports 2025; (15(1)):6796 doi:10.1038/s41598-025-89915-z.

    PMID: 40000769
  12. 12

    Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.

    Xu L, Zhao Y, Chen Z, et al.

    Breast cancer (Tokyo, Japan) 2015; (22(4)):327-34 doi:10.1007/s12282-015-0619-6.

    PMID: 26022977
  13. 13

    Incidence of endometrial cancer in BRCA mutation carriers.

    Kotsopoulos J, Lubinski J, Huzarski T, et al.

    Gynecologic oncology 2024; (189()):148-155 doi:10.1016/j.ygyno.2024.07.687.

    PMID: 39173195
  14. 14

    Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Nelson HD, Fu R, Zakher B, et al.

    JAMA 2019; (322(9)):868-886 doi:10.1001/jama.2019.5780.

    PMID: 31479143

This page provides general cancer screening guidelines for individuals with HBOC or BRCA mutations for educational purposes. Always consult your oncologist or genetic counselor to create a personalized surveillance plan.

Get notified when new evidence is published on Hereditary breast and/or ovarian cancer syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.